The company reported revenues of $1.3 billion for the first quarter of 2021 (end-April 4), which is a 100% increase from the $652 million in revenues posted during the same period in 2020. Net income for the first quarter of 2021 is $379 million, which is a sharp rise from the $33.7 million reported during the same period in 2020.

For the company's discovery division, a 14% increase in revenue of $455 million was reported for the first quarter of 2021. Revenues were $398 million for the first quarter of 2020. Continuing operations income was $43 million in quarter one of 2021, compared to $29 million during the same period of 2020.

For the diagnostics division, the company reported a 236% increase of $853 million in revenues during the first quarter of 2021. During that same period in the year before, revenues were $254 million. Operating income from continuing operations was $441 million in the first quarter of 2021, compared to $30 million for the same quarter in 2020.

PerkinElmer contributes to PROTACs research
PerkinElmer is serving as a provider and co-developer of assays, instruments, and expertise for the ProxiDrugs Consortium, which is zeroing in on research...

Horizon Discovery offers new CRISPR reagents
Horizon Discovery, a PerkinElmer company, is expanding its gene editing and modulation portfolio to include a new family of CRISPR modulation reagents...

PerkinElmer launches free COVID-19 data dashboards
PerkinElmer has launched two free, open access COVID-19 data dashboards to speed up the discovery of antivirals and vaccines for the infection.

PerkinElmer predicts 12% growth in Q2
PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.

PerkinElmer Q1 revenues edge up, profit edges down
In financial results for the first quarter, PerkinElmer saw revenues grow slightly, but net income slipped.